Novel Osteoporosis Medications – Insights from High BMD Disorders
Professor Manju Chandran, Senior Consultant and Director, Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Chairperson, Asia Pacific Consortium on Osteoporosis
Learn how an increased understanding of the pathophysiology of these disorder gives insight into the development of new targeted osteoporosis therapies.
Renal osteodystrophy, osteoporosis, or both?
Professor John Cunningham, The Centre for Nephrology, The Royal Free and University, College Medical School, London
In this module you will learn the impact of progressive chronic kidney disease (CKD) on fracture incidence and morbidity.
Fracture risk in osteoporosis – when to use anabolic therapy
Professor Eugene McCloskey, Professor in Adult Bone Diseases, The Mellanby Centre, Department of Human Metabolism, Faculty of Medicine, Dentistry and Health, University of Sheffield, United Kingdom
Learn about the pathophysiology of osteoporosis and therapies available for its treatment across the spectrum of fracture risk.
